BLAINJECTIONINJECTABLE
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Mechanism of Action
Neonatal Fc Receptor Blockers
Pharmacologic Class:
Neonatal Fc Receptor Blocker
Clinical Trials (2)
Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)
Started Jul 2025
18 enrolled
Epidermolysis Bullosa (EB)Epidermolysis Bullosa AcquisitaRecessive Dystrophic Epidermolysis Bullosa+1 more
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Started Nov 2024
680 enrolled
Myasthenia Gravis